1
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
Condition(s):Head and Neck CancerLast Updated:January 7, 2021Terminated
Durvalumab: 549 Clinical Trials, Page 1 of 55
Hide Studies Not Open or Pending
2
Durvalumab and Tremelimumab for Pediatric Malignancies
Condition(s):Pediatric Cancer; Solid Tumor Pediatric; Hematological MalignanciesLast Updated:February 26, 2021Recruiting
3
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Condition(s):Stage III Non-small-cell Lung CancerLast Updated:March 10, 2021Recruiting
4
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Condition(s):SCLC, Extensive StageLast Updated:February 21, 2021Not yet recruiting
5
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Condition(s):Bladder CancerLast Updated:November 4, 2020Recruiting
6
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:November 12, 2020Recruiting
7
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Condition(s):Colorectal Cancer; Solid TumorLast Updated:February 25, 2021Recruiting
8
Trial Evaluating the Tolerance and Safety of Durvalumab – RT Combination for Treatment in SCCHN
Condition(s):HNSCCLast Updated:April 9, 2020Recruiting
9
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
Condition(s):Non Small Cell Lung Cancer; Renal Cell CarcinomaLast Updated:November 17, 2020Withdrawn
10
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
Condition(s):Small Cell Lung Cancer (SCLC)Last Updated:February 2, 2021Recruiting